Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades our understanding of disease pathogenesis has substantially evolved and novel compounds have been developed cons...
Main Authors: | Spagnolo, P. (Author), Maher, T.M (Author), Richeldi, L. (Author) |
---|---|
Format: | Article |
Language: | English |
Published: |
2015-05-03.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Current and novel drug therapies for idiopathic pulmonary fibrosis
by: Adamali HI, et al.
Published: (2012-09-01) -
Recent advances in understanding idiopathic pulmonary fibrosis [version 1; referees: 2 approved]
by: Cécile Daccord, et al.
Published: (2016-05-01) -
Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
by: Michael Kreuter, et al.
Published: (2015-01-01) -
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges
by: Spagnolo Paolo, et al.
Published: (2012-11-01) -
Idiopathic pulmonary fibrosis: current challenges and future perspectives
by: Luca Richeldi
Published: (2013-06-01)